HKG:1244

2 stories mentioning HKG:1244Updated 28d ago

Every FINWIRES story that references HKG:1244, newest first.

What's the latest news on HKG:1244?

3D Medicines Says Arbitration Award From Sellas Life Sciences Fully Settled

3D Medicines (HKG:1244) said it has received full payment of HK$8 million awarded by an arbitrator in its dispute with Sellas Life Sciences Group, according to a Tuesday Hong Kong bourse filing.The sole arbitrator had dismissed all claims by Sellas and ordered it to cover 3D Medicines' arbitration costs.The company said the award has now been fully settled and will not affect the validity or subsequent performance of the license agreement.

HKG:1244

Asia116d ago

3D Medicines Completes Enrollment Early in Lung Cancer Trial

3D Medicines (HKG:1244) said enrollment was completed ahead of schedule in a phase 3 clinical trial of Envafolimab for the neoadjuvant and adjuvant treatment of non-small cell lung cancer, according to a Thursday Hong Kong bourse filing.Shares of the cancer therapy developer gained over 1% in late-morning trade on Friday.The randomized, double-blind, multi-center study is evaluating Envafolimab combined with platinum-based chemotherapy in patients with resectable stage 3 non-small cell lung cancer.The trial, co-developed with Alphamab Oncology (HKG:9966), enrolled about 390 patients across around 60 clinical research centers in China.

HKG:1244HKG:9966

Track with the FINWIRES app suite

FolioX

Track HKG:1244 in your portfolio

WheelAI

Analyze HKG:1244 options with the wheel strategy

StockInsider

See market sentiment on HKG:1244